CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/14/2026

1. ORCL
2. NVDA
3. SPY
4. USO
5. SRRK
6. DFTX
7. AZN
8. CGEM
9. SATL
10. LYNX

Go back to CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
CalAmp Corp. (NASDAQ: CAMP) Delayed: 4.44 +0.19 (4.47%)
Previous Close $4.25    52 Week High $21.34 
Open $4.26    52 Week Low $12.13 
Day High $4.46    P/E 3.34 
Day Low $4.18    EPS $1.33 
Volume 66,738